-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QJEGNNFvKbNqkYObzduHP13vgJwwjtEdUthHS/dsLmKFmdiruVX2ZWnVMwnk4J7J 1WRKeYvfNnGFvyn0Oj2Fhw== 0001013762-05-001943.txt : 20051223 0001013762-05-001943.hdr.sgml : 20051223 20051223172655 ACCESSION NUMBER: 0001013762-05-001943 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051223 DATE AS OF CHANGE: 20051223 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Chen Bo CENTRAL INDEX KEY: 0001347573 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: BUSINESS PHONE: 212-566-0499 MAIL ADDRESS: STREET 1: C/O NEW YORK GLOBAL GROUP,INC STREET 2: 14 WALL STREET, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: China Natural Gas, Inc. CENTRAL INDEX KEY: 0001120830 STANDARD INDUSTRIAL CLASSIFICATION: REFRIGERATION & SERVICE INDUSTRY MACHINERY [3580] IRS NUMBER: 980231607 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-61883 FILM NUMBER: 051285930 BUSINESS ADDRESS: STREET 1: TANG XING SHU MA BUILDING, SUITE 418 STREET 2: TANG XING ROAD CITY: XIAN, SHAANXI PROVINCE STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-29-88323325 MAIL ADDRESS: STREET 1: TANG XING SHU MA BUILDING, SUITE 418 STREET 2: TANG XING ROAD CITY: XIAN, SHAANXI PROVINCE STATE: F4 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: COVENTURE INTERNATIONAL INC DATE OF NAME CHANGE: 20020528 FORMER COMPANY: FORMER CONFORMED NAME: LIQUIDPURE CORP DATE OF NAME CHANGE: 20000801 SC 13D 1 dec232005form13chenbo.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. ) CHINA NATURAL GAS, INC. ________________________________________________________________________________ (Name of Issuer) Common Stock, par value $.0001 per share ________________________________________________________________________________ (Title of Class of Securities) 168910 10 7 ________________________________________________________________________________ (CUSIP Number) Mr. Chen Bo Bodisen Biotech, Inc. North Part of Xinquia Road, Yang Ling Agricultural High-Tech Industries Demonstration Zone, Yang Ling, People's Republic of China 712100 86-29-87074957 ________________________________________________________________________________ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 6, 2005 ________________________________________________________________________________ (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ?. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 5 Pages) ________________________________________________________________________________ CUSIP No. 222891 10 3 13D Page 2 of 5 Pages ________________________________________________________________________________ 1 NAME OF REPORTING PERSONS Yangling Bodisen Biotech Development Co., Ltd. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS n/a ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* OO ________________________________________________________________________________ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) |_| ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION China ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF SHARES 515,942 shares of common stock. _________________________________________________________ BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 0 _________________________________________________________ EACH REPORTING 9 SOLE DISPOSITIVE POWER 515,942 shares of common stock. _________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 0 _________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 515,942 shares of common stock. ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.2% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* CO ________________________________________________________________________________ Page 3 of 5 Pages Item 1. Security and Issuer. This statement relates to shares of the common stock, par value $.0001 per share, of China Natural Gas, Inc. (formerly Coventure International Inc.), a Delaware corporation (the "Company"). The principal executive offices of the Issuer are presently located at Tang Xing Shu Ma Building, Suite 418, Tang Xing Road, Xian High Tech Area, Xian, Shaanxi Province, China. Item 2. Identity and Background. This statement is being filed by Yangling Bodisen Biotech Development Co., Ltd., a company formed under the laws of the Peoples Republic of China ("Bodisen"). Bodisen is a wholly-owned subsidiary of Bodisen Biotech, Inc., a corporation formed under the laws of the state of Delaware. Bodisen maintains an office at North Part of Xinquia Road, Yang Ling Agricultural, High-Tech Industries Demonstration Zone, Yang Ling, People's Republic of China. On December 6, 2005, the Company entered into and closed a share purchase agreement with Xian Xilan Natural Gas Co., Ltd., a corporation formed under the laws of the People's Republic of China ("Xilan"), and each of Xilan's shareholders, including Bodisen (the "Purchase Agreement"). Pursuant to the Agreement, the Company acquired all of the issued and outstanding capital stock of Xilan from the Xilan shareholders in exchange for 4,000,000 shares of Company common stock. In connection with the acquisition of Xilan on December 6, 2005, Chen Bo, President and a member of the Board of Directors of Bodisen Biotech, Inc. will be appointed as a member of the Board of Directors the Company. During the past five years, neither Mr. Bo nor Bodisen has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors, if any), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result thereof was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. The sole source of consideration for the issuance of the shares of the Company owned by Bodisen was the tender of their ownership of outstanding shares of Xilan pursuant to the Purchase Agreement. Item 4. Purpose of Transaction. See Item 2 above. Item 5. Interest in Securities of the Issuer. Under the rules and regulations of the Securities and Exchange Commission, Bodisen beneficially owns 515,942 shares of common stock, representing 10.2% of the outstanding shares of common stock of the Company. The percentage of outstanding shares of common stock is computed based on 5,051,022 shares of common stock outstanding. Except for the transactions described herein, neither Mr. Bo nor Bodisen has any plans, arrangements or agreements for the acquisition or issuance of additional shares of the Company's common stock or other securities convertible into equity securities of the Company. Page 4 of 5 Pages Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None. Item 7. Material to be Filed as Exhibits. 1. Securities Purchase Agreement dated as of December 6, 2005, by and among Coventure International Inc., Xian Xilan Natural Gas Co.,Ltd. and each of Xilan's shareholders (incorporated by reference to the Company's Form 8-K filed on December 9, 2005). SIGNATURES ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate. December 19, 2005 YANGLING BODISEN BIOTECH DEVELOPMENT CO, LTD. By: /s/ CHEN BO --------------- Name: Chen Bo Title: President -----END PRIVACY-ENHANCED MESSAGE-----